The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000683336
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/05/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Do calcium capsules reduce blood glucose in response to a meal in individuals with type 2 diabetes?
Scientific title
Does oral calcium reduce postprandial blood glucose in type 2 diabetes (T2D)?
Additional trial identifiers [1] 316607 0
N/A
Universal Trial Number (UTN)
Trial acronym
CaT2D
Related trial records

Health condition
Health condition(s) studied:
Type 2 diabetes 341492 0
Condition category
Condition code
Metabolic and Endocrine 337578 337578 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Each participant will be studied on three occasions, separated by at least 7 days in a double-blind, randomised, cross-over fashion. They will be instructed to discontinue oral anti-diabetic medications (e.g. metformin) for 48 h, avoid vigorous physical activity and alcohol for 24 hours, and to consume a standardised meal (beef lasagne; energy content: 602 kcal; McCain Food, Wendouree, Victoria, Australia) by 7 pm the night prior to each study visit. No additional food or drink will be permitted after 7 pm, except for water, which can be consumed until 9:30 pm to ensure hydration.

Each participant will arrive at the Adelaide University Clinical Research Facility by 8 am. Premenopausal female participants will undergo a pregnancy test using a urine sample before each study visit. Upon arrival and confirmation that the participant had fasted as required, they will then be seated, and an intravenous cannula will be placed into a forearm vein for blood sampling. A baseline blood sample (9 mL) to measure fasting plasma concentrations of glucose and hormones (e.g. insulin, glucagon, glucagon-like peptide-1), and a visual analogue scale questionnaire to assess gastrointestinal symptoms and appetite perceptions, will be collected. Then, a blood pressure cuff will be placed around their opposite arm connected to an automated DINAMAP machine, and blood pressure and heart rate measurements will be taken at baseline and at 15-minute intervals over the subsequent hour. At t=-60 min, participants will consume enteric-coated capsules containing either 0 (placebo; cellulose), 500, or 1000 mg of calcium (in the form of calcium citrate tetrahydrate), prepared at the Royal Adelaide Hospital pharmacy. Immediately before the ingestion of a nutrient drink, 3 consecutive blood pressure and heart rate measurements will be taken every 3 min to define the average baseline systolic blood pressure (i.e. t=-9, -6, -3 min). Then at t=-1 min, they will consume, within 1 min, a mixed-nutrient drink (Resource Plus, Nestle; 325 ml, 500 kcal, 74 g carbohydrates, 18 g protein and 15 g fat, plus 25 mL water), labelled with 100 mg sodium acetate-1-13C for measurement of gastric emptying by non-invasive breath sampling. The timing of calcium administration is based on previous studies indicating the maximum effects of intraduodenal calcium on plasma hormones and pyloric pressures. Further blood pressure and heart rate measurements will be recorded at 5-minute intervals from t=0 to t=180 min. Breath samples will be collected in sealed bags at baseline (prior to the mixed-nutrient drink) and at regular intervals (every 5 min for the first hour and then 15 min for the subsequent two hours) between t=0 to t=180 min, for analysis of 13CO2. Visual analogue scale scores and 9-mL blood samples will be collected every 30 min after the mixed-nutrient drink (at t=30, 60, 90, 120, 150, 180 min) to assess postprandial effects. At t=180 min, the final blood pressure and heart rate measurements, blood and breath samples, and visual analogue scale scores, will be collected, the i.v. cannula will be removed (after making sure that blood glucose is >5 mmol/L), and the participant will then be allowed to leave the laboratory.
Intervention code [1] 333764 0
Treatment: Other
Intervention code [2] 334186 0
Treatment: Drugs
Description of the comparator or control
cellulose capsules
Control group
Placebo

Outcomes
Primary outcome [1] 345063 0
Postprandial plasma glucose
Timepoint [1] 345063 0
Plasma glucose will be assessed from venous blood samples during each treatment condition (control, 500 and 1000 mg of calcium), taken at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [1] 460335 0
Gastric emptying of a standardised mixed-nutrient drink
Timepoint [1] 460335 0
Breath samples will be collected during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), immediately before the mixed-nutrient drink (t=-1 min), and at regular intervals (every 5 min for the first hour and then 15 min for the subsequent two hours) between t=0 to t=180 min.
Secondary outcome [2] 460336 0
Gut and pancreatic hormones (glucagon-like peptide-1, insulin, glucagon)
Timepoint [2] 460336 0
Plasma concentrations of hormones will be assessed from venous blood samples during each treatment condition (control, 500 and 1000 mg of calcium), taken at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [3] 460339 0
Blood pressure
Timepoint [3] 460339 0
Blood pressure will be taken during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), an then at 15-minute intervals over the subsequent hour, Immediately before the ingestion of a nutrient drink,consecutive blood pressure measurements will be taken every 3 min (to define the average baseline systolic blood pressure), Further blood pressure measurements will be recorded at 5-minute intervals from t=0 to t=180 min.
Secondary outcome [4] 460353 0
Nausea
Timepoint [4] 460353 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [5] 460354 0
Bloating
Timepoint [5] 460354 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [6] 461648 0
Hunger
Timepoint [6] 461648 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [7] 461649 0
Fullness
Timepoint [7] 461649 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [8] 461650 0
Desire to eat
Timepoint [8] 461650 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [9] 461651 0
Amount of food desired to eat
Timepoint [9] 461651 0
Visual analogue scale questionnaire will be completed during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), in response to calcium or control (t= -30, and -1 min), and then at regular time points for 3 hours following the mixed-nutrient drink (t= 30, 60, 90, 120, 150, and 180 min).
Secondary outcome [10] 462073 0
Heart rate
Timepoint [10] 462073 0
Hearth rate will be taken during each treatment condition (control, 500 and 1000 mg of calcium), at baseline (t=-60 min), an then at 15-minute intervals over the subsequent hour, Immediately before the ingestion of a nutrient drink,consecutive heart rate measurements will be taken every 3 min. Further heart rate measurements will be recorded at 5-minute intervals from t=0 to t=180 min.

Eligibility
Key inclusion criteria
People with T2D (World Health Organisation criteria) and BMI > 25 kg/m2
Minimum age
45 Years
Maximum age
70 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
-Weight change of more than ±5.0% during the three months prior to screening
-History of ketoacidosis or hyperosmolar state/coma
-History of severe hypoglycaemia resulting in seizure/unconsciousness/coma or hospitalisation for diabetic ketoacidosis in the last 3 months before screening.
-Hypoglycaemia unawareness
-Have a known clinically significant gastric emptying abnormality (e.g., severe diabetic gastroparesis or gastric outlet obstruction).
-Significant GI symptoms, disease or surgery, current gallbladder or pancreatic disease, cardiovascular or respiratory diseases, or any other illness, including chronic conditions not explicitly listed, as assessed by the investigator
-Use of prescribed or non-prescribed medications, including vitamins and herbal supplements which may affect energy metabolism, GI function, body weight or appetite (e.g. domperidone, cisapride, anticholinergic drugs (e.g. atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St John’s wort, etc.)
-Individuals with low ferritin levels (females less than 15 ng/mL, males less than 30 ng/mL)
-Estimated glomerular filtration rate (eGFR) less than 45 mL/min, used as a measure of kidney function
-History of / or current active liver disease (other than non-alcoholic hepatic steatosis), primary biliary cirrhosis, or active symptomatic gallbladder disease
-History of any clinically significant disease or disorder that may either put the volunteer at risk because of participation in the study, or influence the results or the ability of the volunteer to participate in the study
-Baseline SBP less than or equal to 100mmHg
-Current tobacco smokers (e.g. cigarettes, cigars, pipes, sheesha, chewing, vaping, etc.)
-Recreational drug use (e.g. marijuana) or current intake of any illicit substance
-Current intake of greater than 2 standard drinks on > 5 days per week
-Lactose intolerance/other food allergy(ies)
-Vegetarians
-High-performance athletes
-Inability to comprehend study protocol
-In female participants, pregnancy, lactation or surgical sterilisation (a pregnancy test will be performed in premenopausal female volunteers, using a urine sample, prior to each study day)
-Autonomic nerve function will be evaluated using standardised cardiovascular reflex tests. Patients will be excluded from the study if autonomic nerve damage is diagnosed, i.e. if they achieve a score greater than or equal to 3.
-Donated blood in the past 3 months

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Eligible volunteers are assigned a participant number and randomised treatment for each study visit. Randomisation involves contacting the holder (study assistant) of the allocation schedule to inform her of participant details and study dates. The unblinded study assistant will be, therefore, responsible for allocating a random treatment to the participant and preparing and administrating that on the study days.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be carried out using an online tool (https://www.sealedenvelope.com/).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint/s
Pharmacodynamics
Statistical methods / analysis
All data will be encrypted to ensure the confidentiality of participant information. Statistical analyses will be conducted in collaboration with a biostatistician. Data for plasma glucose, gastric emptying, hormone concentrations, appetite perceptions, gastrointestinal symptoms, and blood pressures and heart rates will be analysed using repeated-measures analysis of variance (ANOVA), with time and treatment as factors. One-way ANOVA will be used to analyse the area under the curve (AUC) data for plasma glucose. Post-hoc paired comparisons, corrected for multiple comparisons, will be performed if ANOVAs reveal significant effects. Relationships between the outcomes will be evaluated using regression analysis.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA

Funding & Sponsors
Funding source category [1] 321227 0
Charities/Societies/Foundations
Name [1] 321227 0
Australian Diabetes Society (ADS)
Country [1] 321227 0
Australia
Primary sponsor type
Individual
Name
Dr Javad Anjom Shoae - Adelaide University
Address
Country
Australia
Secondary sponsor category [1] 323934 0
Individual
Name [1] 323934 0
Professor Michael Horowitz - Adelaide University
Address [1] 323934 0
Country [1] 323934 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319753 0
Central Adelaide Local Health Network HREC
Ethics committee address [1] 319753 0
Ethics committee country [1] 319753 0
Australia
Date submitted for ethics approval [1] 319753 0
27/02/2026
Approval date [1] 319753 0
14/05/2026
Ethics approval number [1] 319753 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148294 0
Dr Javad Anjom Shoae
Address 148294 0
School of Medicine, College of Health, Adelaide University, Level 5 Adelaide Health and Medical Sciences Building, Cnr George St and North Tce Adelaide, SA 5005
Country 148294 0
Australia
Phone 148294 0
+61 478 601 953
Fax 148294 0
Email 148294 0
Contact person for public queries
Name 148295 0
Javad Anjom Shoae
Address 148295 0
School of Medicine, College of Health, Adelaide University, Level 5 Adelaide Health and Medical Sciences Building, Cnr George St and North Tce Adelaide, SA 5005
Country 148295 0
Australia
Phone 148295 0
+61 478 601 953
Fax 148295 0
Email 148295 0
Contact person for scientific queries
Name 148296 0
Javad Anjom Shoae
Address 148296 0
School of Medicine, College of Health, Adelaide University, Level 5 Adelaide Health and Medical Sciences Building, Cnr George St and North Tce Adelaide, SA 5005
Country 148296 0
Australia
Phone 148296 0
+61 478 601 953
Fax 148296 0
Email 148296 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.